Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
- Conditions
- Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 32
- Registration Number
- NCT01889797
- Locations
- 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 131
- Registration Number
- NCT01797120
- Locations
- 🇺🇸
Marin Cancer Care, Greenbrae, California, United States
🇺🇸SwedishAmerican Regional Cancer Center, Rockford, Illinois, United States
🇺🇸McFarland Clinic, PC, Ames, Iowa, United States
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Phase I- Cytarabine & EltrombopagDrug: Phase II- Sequence BDrug: Phase II- Sequence A
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 15
- Registration Number
- NCT01656252
- Locations
- 🇺🇸
University of Massachusetts Worcester, Worcester, Massachusetts, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Mayo Clinic, Rochester, Rochester, Minnesota, United States
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 3
- Registration Number
- NCT01649180
- Locations
- 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
- Conditions
- Multiple MyelomaPlasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 63
- Registration Number
- NCT00790842
- Locations
- 🇺🇸
Metro MN CCOP, Saint Louis Park, Minnesota, United States
🇺🇸Emory University Winship Cancer, Atlanta, Georgia, United States
🇺🇸Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
- Conditions
- Lung CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 162
- Registration Number
- NCT00687297
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Ocean Medical Center, Brick, New Jersey, United States